Stock PHAR PHARMING GROUP N.V.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pharming Group N.V. Nasdaq

Equities

PHAR

US71716E1055

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-05-24 pm EDT 		5-day change 1st Jan Change
9.31 USD +2.87% Intraday chart for Pharming Group N.V. +0.11% -18.55%
May. 21 Transcript : Pharming Group N.V. - Shareholder/Analyst Call
May. 08 Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

  • Growth progress expectations are rather promising. Indeed, sales are expected to rise sharply in the coming years.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
  • The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company sustains low margins.
  • For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PHARMING GROUP N.V. Stock Pharming Group N.V.
-18.55% 608M -
ELI LILLY AND COMPANY Stock Eli Lilly and Company
+38.51% 727B
C+
NOVO NORDISK A/S Stock Novo Nordisk A/S
+33.05% 599B
B
JOHNSON & JOHNSON Stock Johnson & Johnson
-6.23% 354B
C+
MERCK & CO., INC. Stock Merck & Co., Inc.
+18.78% 328B
B-
ABBVIE INC. Stock AbbVie Inc.
+1.35% 277B
C+
ASTRAZENECA PLC Stock AstraZeneca PLC
+16.00% 243B
B+
NOVARTIS AG Stock Novartis AG
+8.09% 205B
B-
ROCHE HOLDING AG Stock Roche Holding AG
-5.77% 203B
A+
AMGEN INC. Stock Amgen Inc.
+6.19% 164B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. PHARM Stock
  4. PHAR Stock
  5. Ratings Pharming Group N.V.